- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01050946
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit (Haplo/Cord)
Phase II Study: HSCT Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
This study is a means of providing transplantation to those patients who would be a stem cell transplant candidate who do not have an appropriate donor.
The use of CD34 selected haploidentical donor with an umbilical cord unit may help provide earlier engraftment without the need for long term immunosuppression.
This study tests a new method of bone marrow transplantation called combined haploidentical-cord blood transplantation. In this procedure, some of the blood forming cells (the stem cells) from a partially human leukocyte antigen (HLA) matched (haploidentical) related donor are collected from the blood, as well as cells from an umbilical cord are transplanted into the patient (the recipient) after administration of a "conditioning regimen". A conditioning regimen consists of chemotherapy and sometimes radiation to the entire body (total body irradiation, or TBI), which is meant to destroy the cancer cells and suppress the recipient's immune system to allow the transplanted cells to take (grow).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This method of stem cell transplantation is designed to overcome some of the limitations of other alternative donor transplant options. Use of unrelated umbilical cord unit (UCB) donors appears to allow a greater degree of HLA mismatch with acceptable rates of GVHD. However, when UCB transplant was studied in the adult population, investigators discovered several limitations. One major limitation with UCB was delayed engraftment, resulting in higher risk of infection in the early post transplant period. The limitations to cord blood transplant involve delayed engraftment resulting in early complications such as infections. The main limitation associated with haploidentical donors is the significant immunosuppression required to prevent/treat aGVHD. Use of this combined modality of transplantation appears to allow for rapid neutrophil engraftment from the haploidentical donor and coupled with long term hematopoiesis from the UCB donor, thus requiring less long term immunosuppression.
This study tests a new method of bone marrow transplantation called combined haploidentical-cord blood transplantation. In this procedure, some of the blood forming cells (the stem cells) from a partially HLA matched (haploidentical) related donor are collected from the blood, as well as cells from an umbilical cord are transplanted into the patient (the recipient) after administration of a "conditioning regimen". A conditioning regimen consists of chemotherapy and sometimes radiation to the entire body (total body irradiation, or TBI),
One of two 'conditioning regimens' which will be determined by the physician.
FLUDARABINE, MELPHALAN, ATG
Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)
- FLUDARABINE, BUSULFAN, 400 CGY TBI, ATG Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2) 400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)
Day 0 -Haploidentical donor and one umbilical cord blood unit infusion
Filgrastim will be administered daily from day +1 until blood counts have completely recovered. Tacrolimus and another immunosuppressant, Cellcept, starting before transplant also to reduce the risks of graft versus host disease and to promote the growth of the graft. Tacrolimus will be given daily from two days before the transplant until at least three months after transplantation. Cellcept, will be tapered after the cells engraft.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients between 18 and 65 years old
- Patient has a related family member(haploidentical) or unrelated which is 5 of 10 HLA identical match.
Standard Risk
- Acute myelogenous leukemia: CR1 with high risk cytogenetics or molecular abnormalities such as FLT-3 ITD, or CR2 with a first remission that must have lasted > 1 year.
- Acute Lymphocytic Leukemia: CR1, in order to be standard risk must NOT have Philadelphia Chromosome.
- Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Must be refractory to fludarabine or fail to have a complete or partial response after therapy with a regimen containing fludarabine (or another nucleoside analog, e.g. 2-CDA, pentostatin) or experience disease relapse within 12 months after completing therapy with a regimen containing fludarabine (or another nucleoside analog).
- Chronic myelogenous leukemia: resistant to or intolerant of TKI, in CP1 or CP2, or with a mutation that suggests resistance to TKI.
- Myelodysplastic Syndrome: RA, RARS, must be IPSS ≥ INT-2, Blasts <5%.
High Risk Patients:
- Acute myelogenous leukemia: Patients with CR2 are considered high risk if they have high risk cytogenetics, or molecular abnormalities or CR1 lasted for less than 1 year. Any evidence of active disease or no blasts in an acellular marrow.
- Acute Lymphocytic Leukemia: CR1- with Ph+ disease, CR2/+ with any cytogenetics. Any evidence of active disease.
- Chronic myelogenous leukemia- CP2/+, AP1/+, resistant or intolerant to TKI.
- Hodgkin's or Non Hodgkin's lymphoma- Disease recurrence following an autologous transplant, or high risk disease not thought to benefit from autologous transplant.
- Chronic lymphocytic leukemia- that is resistant to fludarabine, and never has been in remission or with stable disease/progressive disease
- Multiple myeloma: Must have had prior treatment. Patients in CR2 or greater can be considered, must have already failed autologous transplant Previous autologous transplant,must have been greater than 6 months prior to undergoing this transplant.
- Myelodysplastic syndrome: RAEB
- Other Myeloproliferative disorders including myelofibrosis, spent phase p Vera,Essential thrombocytosis,CMML.
Exclusion Criteria:
- Patients <18 years old Disease related criteria
- APML, presence of t(15,17) in first CR
- Patients with good risk AML, for example t(8;21), or inv 16, or normal cytogenetics with FLT-3-ITD negative, NPM-1 positive disease in 1st CR
- MDS IPSS < INT-2 Miscellaneous Criteria
- Recipients who have a matched related sibling or unrelated donor
- If recipient has evidence of anti-HLA antibodies directed against cord or haplo-donor as determined byflowPRA.
Underlying health criteria:
- Zubrod performance status > 2 (see Appendix E)
- Life expectancy is limited to less than 8 weeks by concomitant illness
- Patients with severely decreased LVEF (EF < 40%)
- Impaired pulmonary function tests (PFT's) (FVC, FEV1, DLCO < 45% predicted)
- Estimated Creatinine Clearance <50 ml/min
- Serum bilirubin> 2.0 mg/dl or SGPT >3 x upper limit of normal
- Evidence of chronic active hepatitis or cirrhosis
- HIV-positive
- Patient is pregnant
- Patient or guardian not able to provide informed consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Autre: Haploidentical/cord transplant
Haploidentical/cord transplant with the precondition regimen at discretion of treating physician.
|
Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation. Conditioning Regimens Choice of regimen at the discretion of the treating physician
Day 0 -Haploidentical donor and one umbilical cord blood unit infusion
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
The Primary Objective is to Estimate the Overall Survival, Separately in the Two Risk Strata.
Délai: 3 years
|
3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Time to Relapse: To Assess the Incidence of Acute Leukemia or Lymphoma Relapse From Day of Transplant
Délai: 2 years
|
NOT analyzed since there was only patient and no relapse was observed till patient passed away
|
2 years
|
Time to Neutrophil Engraftment: To Assess the Incidence of Neutrophil Engraftment From Day of Transplant
Délai: 100 days
|
time to neutrophil recovery after transplant
|
100 days
|
Time to Platelet Engraftment: To Assess the Incidence of Platelet Engraftment From Day of Transplant,
Délai: 100 days
|
100 days
|
|
Time to Acute GVHD: We Will Assess the Incidence and Severity of Grades II-IV and Grades III-IV Acute GVHD From Day of Transplant.
Délai: 100 days
|
100 days
|
|
Transplant Related Mortality (TRM): TRM is Death Occurring in Patients in Continuous Complete Remission.
Délai: 1 year
|
1 year
|
|
Disease-free Survival:Death or Relapse Will be Considered Events for This Endpoint.
Délai: 3 years
|
3 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jeanne Palmer, M.D., Medical College of Wisconsin
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- LAM
- LNH
- TOUT
- Lymphome non hodgkinien
- LMC
- HL
- Leucémie, lymphocytaire, aiguë
- Leucémie, myéloïde, chronique
- Leucémie, myélocytaire, aiguë
- Haploidentical donor
- Unrelated Umbilical Cord Blood Transplant(UCB)
- CD34+ Selected mismatched related donor
- hematopoietic stem cell transplantation(HSCT)
- Lymphoma, Hodgkins
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Tumeurs
- Troubles lymphoprolifératifs
- Maladies lymphatiques
- Troubles immunoprolifératifs
- Maladies de la moelle osseuse
- Maladies hématologiques
- Troubles myéloprolifératifs
- Leucémie, cellule B
- Lymphome
- Leucémie
- Leucémie myéloïde
- Leucémie, myéloïde, aiguë
- Maladie de Hodgkin
- Lymphome non hodgkinien
- Leucémie-lymphome lymphoblastique à cellules précurseurs
- Leucémie lymphocytaire chronique à cellules B
- Leucémie, Lymphoïde
- Leucémie, myéloïde, chronique, BCR-ABL positif
Autres numéros d'identification d'étude
- MCW 11491
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Lymphome non hodgkinien
-
Shandong Provincial HospitalInconnueApplication clinique de la doxorubicine (PLD) liposome polyéthylène glycol dans le lymphome primaireLymphome non hodgkinien ; maladie de HodgkinChine
-
University Hospital, BrestComplétéImagerie diagnostique | Lymphome non hodgkinien récidivant | Maladie de Hodgkin en rechute, adulte | Lymphome malin
-
Baylor College of MedicineNational Cancer Institute (NCI); The Methodist Hospital Research Institute; Center...Actif, ne recrute pasMaladie de Hodgkin | Lymphome de Hodgkin | Lymphome non hodgkinienÉtats-Unis
-
TakedaComplétéLymphome de Hodgkin CD30-positif non traitéJapon
-
CytokineticsComplétéLymphome non hodgkinien | La maladie de HodgkinÉtats-Unis, Fédération Russe
-
Tomsk National Research Medical Center of the Russian...Uppsala UniversityComplétéLymphome hodgkinien, adulte | Lymphome non hodgkinien, adulteFédération Russe
-
TakedaComplétéMaladie de Hodgkin | Lymphome anaplasique à grandes cellulesChine
-
AstraZenecaRecrutementLymphome | Lymphome de Hodgkin | Non hodgkinienCorée, République de, Royaume-Uni, Italie, Allemagne, France, Espagne, États-Unis, Australie
-
Masonic Cancer Center, University of MinnesotaRecrutementLymphome de Hodgkin | Lymphome non hodgkinienÉtats-Unis
-
The Hospital for Sick ChildrenComplétéLymphome de Hodgkin | Lymphome non hodgkinienCanada
Essais cliniques sur Haploidentical/cord transplant
-
Johns Hopkins UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Pas encore de recrutementLa dépression | Qualité de vie | Phase terminale de la maladie rénale | Handicap PhysiqueÉtats-Unis
-
Tissue Tech Inc.ComplétéUlcères du pied diabétiqueÉtats-Unis, Canada
-
Harbin Medical UniversityComplétéHernie inguinale, sans mention d'obstruction ou de gangrène
-
The University of Texas Health Science Center,...RecrutementMyéloméningocèle | Spina bifida | MyéloschisisÉtats-Unis
-
The University of Texas Health Science Center,...RecrutementMyéloméningocèle | Myéloschisis | Spina-bifida ; FœtusÉtats-Unis
-
SandozComplété
-
Massachusetts General HospitalDana-Farber Cancer InstituteComplétéLymphome de Hodgkin | La leucémie lymphocytaire chronique | Lymphome de bas grade | Lymphome diffus à grandes cellules B | Lymphome T | Lymphome à cellules du manteau | Lymphome à petits lymphocytesÉtats-Unis